Survivin expression in XXXX : correlation with apoptotic markers and prognosis.

@entity43 @entity589 @entity588 @entity5 @entity1836 @entity876
Survivin is a novel inhibitor of apoptosis commonly detected in tissues during fetal development and in @entity5 , but not usually in normal tissues. Expression of this protein may be of prognostic significance and therapeutically relevant in many @entity5 . We assessed survivin expression in @entity43 , correlating results with expression of other anti-apoptotic ( @entity588 , @entity1836 , mutant @entity876 ) and pro-apoptotic ( @entity589 ) markers, with prognostic parameters, and prognosis. Paraffin-embedded sections of 49 @entity43 were immunostained for survivin, @entity588 , @entity1836 , @entity589 , and @entity876 . Expression was evaluated in nuclei and cytoplasm, as intensity (0-3+), and percentage of positive cells was scored on a four-tiered system with <10% as negative. Frequency of survivin, @entity588 , @entity1836 , @entity589 , and @entity876 was 73.5%, 36.7%, 93.9%, 77.6%, and 60.4%, respectively. There was significant correlation between nuclear survivin expression and grade (P =.0014), histologic type (P =.0376), and mutant @entity876 (P =.0414). Survivin expression did not correlate with @entity588 , @entity1836 , or @entity589 expression, stage, or overall or disease-free survival. The majority (74%) of @entity43 show survivin expression, which correlates with poor prognostic parameters (high grade, histologic type, @entity876 mutation) but not with survival. Therapeutic targeting of survivin in @entity43 is a future possibility.
